Systems Pharmacology‐Based Discovery of Natural Products for Precision Oncology Through Targeting Cancer Mutated Genes
MetadataShow full item record
CitationFang, J, C Cai, Q Wang, P Lin, Z Zhao, and F Cheng. 2017. “Systems Pharmacology‐Based Discovery of Natural Products for Precision Oncology Through Targeting Cancer Mutated Genes.” CPT: Pharmacometrics & Systems Pharmacology 6 (3): 177-187. doi:10.1002/psp4.12172. http://dx.doi.org/10.1002/psp4.12172.
AbstractMassive cancer genomics data have facilitated the rapid revolution of a novel oncology drug discovery paradigm through targeting clinically relevant driver genes or mutations for the development of precision oncology. Natural products with polypharmacological profiles have been demonstrated as promising agents for the development of novel cancer therapies. In this study, we developed an integrated systems pharmacology framework that facilitated identifying potential natural products that target mutated genes across 15 cancer types or subtypes in the realm of precision medicine. High performance was achieved for our systems pharmacology framework. In case studies, we computationally identified novel anticancer indications for several US Food and Drug Administration‐approved or clinically investigational natural products (e.g., resveratrol, quercetin, genistein, and fisetin) through targeting significantly mutated genes in multiple cancer types. In summary, this study provides a powerful tool for the development of molecularly targeted cancer therapies through targeting the clinically actionable alterations by exploiting the systems pharmacology of natural products.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:32072092
- HMS Scholarly Articles